Real-world evidence of multiple myeloma treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland

• Published in: Future oncology (London, England) Vol. 19; no. 30; pp. 2029 - 2043
• Main Authors: Vikkula, Johanna, Uusi-Rauva, Kristiina, Ranki, Tuuli, Toppila, Iiro, Aalto-Setälä, Maria, Pousar, Katariina, Vassilev, Lotta, Porkka, Kimmo, Silvennoinen, Raija, Brück, Oscar
• Format: Journal Article
• Language: English
• Published: Future Medicine Ltd 01.09.2023
• Subjects: electronic health record data; healthcare resource use; hospital data lake; immunochemotherapy; multiple myeloma; real-world data/evidence
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2023-0120

The rapid development of multiple myeloma (MM) management underscores the value of real-world data. In our study we examined 509 adult MM patients treated with immunochemotherapy (ICT) with/without stem cell transplantation (SCT) from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland. Our study was based on computational analyses of data integrated into the hospital data lake. After 2017, treatment pattern diversity increased with improved access to novel treatments. 5-year survivals were 74.4% (95% CI: 65.5–84.5) in SCT-eligible and 44.0% (95% CI: 37.6–51.4) in non-SCT subgroups. In the SCT-eligible subgroup, high first-year hospitalization costs were followed by stable resource requirements. Hospital data lakes can be adapted to carry out complex analysis of large MM cohorts. To better understand how multiple myeloma (a type of blood cancer) is clinically managed, we examined 509 adult patients using advanced computer analysis and data stored in the Hospital District of Helsinki and Uusimaa information system. Our study found that after 2017, there was more variety in treatments due to better access to new therapies. Compared with a nontransplant group (44.0%), patients eligible for stem cell transplantation had a better 5-year survival rate (74.4%) and used higher levels of healthcare resources. Our study highlights the potential of hospital data systems to study large groups of multiple myeloma patients and inform strategies to tackle the burden associated with the treatment costs of multiple myeloma. Treatment patterns in multiple myeloma patients are heterogeneous, and have extended in duration in recent years following the adoption of novel modalities – study of >500 multiple myeloma patients with the Helsinki (Finland) data lake @oscarbruck @RaijaSilvennoi1 @kporkka @HUS_fi @medaffcon.